CREATION OF CLONED CATTLE LACKING THE PRION GENE

Information

  • Research Project
  • 2792696
  • ApplicationId
    2792696
  • Core Project Number
    R43NS038382
  • Full Project Number
    1R43NS038382-01
  • Serial Number
    38382
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1999 - 25 years ago
  • Project End Date
    1/31/2001 - 23 years ago
  • Program Officer Name
    KERZA-KWIATECKI, A P
  • Budget Start Date
    8/1/1999 - 25 years ago
  • Budget End Date
    1/31/2001 - 23 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/16/1999 - 25 years ago

CREATION OF CLONED CATTLE LACKING THE PRION GENE

Bovine spongiform encephalopathy (BSE) is a world-wide problem for consumers of agriculture, industrial and medical products. An altered form of the prion (PrP) gene appears to be the causative agent, and an endogenous PrP gene is necessary for infection. Advanced Cell Technology and the University of Massachusetts recently announced the birth of three cloned transgenic calves, George, Charlie and Albert. In phase I of this project, we will extend this work, by creating a targeting vector for the bovine prion gene,, PrP, and optimizing the conditions for electroporation and drug selection in bovine embryonic fibroblasts cells. In phase II, we will create BEF cells and cattle containing a homologously-targeted PrP gene. Based on evidence from PrP knockout mice, we hypothesize that are cloned transgenic animals will be unable to both transmit and contract the prion-based disease, BSE. Thus, the long term goal of this project is to create a strain of cattle to be used: (1) to study PrP function in cattle, (2) as a source of prion-free embryonic tissue to treat neurodegenerative disease (3) to increase the safety profile of bovine derived products for research and pharmaceuticals, and (4) as a source of prion-free food products for consumers. PROPOSED COMMERCIAL APPLICATIONS: Cattle containing a targeted deletion of prion protein can be used commercially (1) as a source of prion-free embryonic tissue to treat neurodegenerative disease (2) to increase the safety profile of bovine-derived products (3) as a source of prion-free food products

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    ADVANCED CELL TECHNOLOGY
  • Organization Department
  • Organization DUNS
  • Organization City
    WORCESTER
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01605
  • Organization District
    UNITED STATES